The system is a compact new addition to the Roche Molecular portfolio, providing efficiency, simplicity and timely results to laboratories of all sizes.
The company performed particularly well in operational eco-efficiency, environmental and social reporting
The implant is surgically inserted into the eye during a one-time, outpatient procedure and refilled every six months
Tecentriq is the first and only cancer immunotherapy approved for NSCLC in the adjuvant setting
New safety data show a consistent benefit-risk profile across all Ocrevus clinical trials
Gantenerumab is an investigational antibody in Phase III development for early Alzheimer's disease (AD) and a comprehensive data set with an expected readout in mid-2022
Cobas pure provides clinical labs with access to more than 230 diagnostic tests across a wide range of disease areas including infectious diseases, oncology and cardiology
Three new molecular diagnostic test panels for influenza and other common respiratory illnesses can be run together or alone using one patient sample
If approved, Gavreto will be the first and only targeted treatment approved by the EMA that includes first-line treatment of people with RET fusion-positive advanced NSCLC
The deal is expected to close in the fourth quarter of 2021 and will enable Roche to further expand the portfolio. TIB Molbiol excels in ultra-rapid assay development of emerging infectious diseases
Subscribe To Our Newsletter & Stay Updated
